Human-derived rotavirus strain as well as culture method and application thereof

By providing human G3P[10] rotavirus strain XYR-19 and its cultivation method, the safety and cost of existing rotavirus vaccines have been solved, and safe and effective rotavirus vaccine development has been achieved. , providing stronger immune protection.

CN118909967APending Publication Date: 2024-11-08INST OF MEDICAL BIOLOGY CHINESE ACAD OF MEDICAL SCI
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410831525.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-06-25
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

The existing rotavirus vaccines, especially live attenuated vaccines, have defects in safety and stability, and the cold chain preservation system is costly, lack of safe and effective inactivated rotavirus vaccines, and human-derived G3P[ 10] Rotavirus strains of type 10 have not been fully studied.

Method used

Provide a human G3P[10] rotavirus strain XYR-19 and its culture method. It is cultured using Vero cells, which has strong viral replication ability and genetic stability, and is used to develop safe and effective rota. Viral vaccine.

Benefits of technology

This strain is used to develop a multivalent inactivated human rotavirus vaccine, providing safer and more effective protective measures, reducing the economic cost of vaccine production, and improving the immunogenicity and stability of the vaccine.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure HDA0004911906000000011
    Figure HDA0004911906000000011
  • Figure HDA0004911906000000012
    Figure HDA0004911906000000012
  • Figure HDA0004911906000000021
    Figure HDA0004911906000000021
Patent Text Reader

Abstract

The invention provides a human rotavirus strain as well as a culture method and application thereof. The invention specifically provides a Rotavirus group A (Rotavirus A), and the preservation number of the Rotavirus group A is CGMCC (China General Microbiological Culture Collection Center) No.26214. The rotavirus group A (Rotavirus A) CGMCC (China General Microbiological Culture Collection Center) No.26214 is a human G3P [10] type human rotavirus strain, the culture method of the rotavirus group A is simple to operate, the culture economic cost is relatively low, and the harvested virus is relatively high in titer and good in immunogenicity. The invention also provides a related application of the rotavirus group A CGMCC No.26214 in preparation of products such as rotavirus vaccines, detection agents, antibodies and the like.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to a human-derived rotavirus strain and a culture method and application thereof. Background Art

[0002] Human rotavirus is one of the most important pathogens causing diarrhea in infants and young children. The typical clinical symptoms of rotavirus infection in young children are vomiting, non-bloody diarrhea and fever. In severe cases, hypertonic dehydration, convulsions and electrolyte imbalance may occur, leading to the death of the child. Rotavirus gastroenteritis may also affect the growth and development of children, causing growth retardation and weight loss. In severe cases, malnutrition may occur and even affect brain development. There is currently no specific treatment for rotavirus gastroenteritis. It is mainly based on the clinical manifestations of the child, using rehydration therapy, diet therapy, oral zinc supplementation and other auxiliary symptomatic and supportive therapies. Rotavirus vaccine is a safe and effective vaccine to prevent diseases caused by rotavirus infection in children.

[0003] Currently, all rotavirus vaccines in preclinical research or on the market are oral live attenuated vaccines. Although live attenuated vaccines have certain effects, they have defects in safety, such as the risk of causing intussusception and virulence reversion mutation and the generation of new mutants; and the cold chain storage system requires high costs. Therefore, the development of a safe and effective inactivated rotavirus vaccine not only has advantages in avoiding problems existing in the use of live attenuated vaccines, but also provides a basis for the future development of combined vaccines.

[0004] The characteristics of rotavirus epidemic strains are the key to the development of rotavirus vaccines, but over time, the types of rotavirus epidemic strains will change. Currently, the types of human rotavirus strains preserved are mainly G1P[8] and G9P[8], and there are no human G3P

[10] rotavirus strains. Summary of the invention

[0005] The present invention aims to provide a G3P

[10] type human rotavirus strain.

[0006] The inventors of this case screened out a G3P

[10] type human rotavirus strain in their research, which is named XYR-19 in the present invention. The strain has been patented. Deposit date: August 7, 2023; deposit unit: General Microbiology Center of China Microbiological Culture Collection Committee (CGMCC); deposit unit address: Institute of Microbiology, Chinese Academy of Sciences, No. 3, Yard No. 1, Beichen West Road, Chaoyang District, Beijing; deposit number: CGMCC No. 26214; classification name: Rotavirus A. The rotavirus strain XYR-19 of the present invention has strong viral replication ability and good genetic stability, and can be used to develop production strains of rotavirus vaccines for human use.

[0007] Specifically, on the one hand, the present invention provides a rotavirus A group (Rotavirus A), whose deposit number is CGMCC No.26214.

[0008] On the other hand, the present invention also provides a microbial preparation, which contains the rotavirus A group (Rotavirus A) CGMCC No. 26214 (or strain XYR-19) of the present invention.

[0009] On the other hand, the present invention also provides a method for culturing rotavirus A group (Rotavirus A) CGMCC No. 26214, which comprises: using Vero cells as cell matrix, inoculating rotavirus A group (Rotavirus A) CGMCC No. 26214 for culturing.

[0010] According to a specific embodiment of the present invention, the culturing method of rotavirus A group (Rotavirus A) CGMCC No. 26214 of the present invention comprises: using Vero cells as a cell matrix, waiting for the Vero cells to grow to a monolayer of cells, the virus inoculation amount is 0.05-0.3 MOI, then adding MEM cell maintenance fluid without calf serum, culturing at 37° C. for 48-120 hours, and harvesting the culture. The culturing method of the present invention is simple to operate and has low culturing economic cost.

[0011] On the other hand, the present invention also provides a nucleic acid of rotavirus A group CGMCC No.26214, specifically, including a nucleic acid specific to rotavirus A group CGMCC No.26214 (i.e., XYR-19). According to a specific embodiment of the present invention, the nucleic acid of rotavirus A group CGMCC No.26214 of the present invention includes one or more of its full gene, VP4 gene, VP7 gene, VP6 gene, and NSP3 gene. According to a specific embodiment of the present invention, the nucleic acid of rotavirus A group CGMCC No.26214 of the present invention may further include one or more of its VP1 gene, VP2 gene, VP3 gene, NSP1 gene, NSP2 gene, NSP4 gene, and NSP5 gene.

[0012] On the other hand, the present invention also provides proteins of rotavirus group A (Rotavirus A) CGMCC No.26214, specifically including proteins specific to rotavirus group A CGMCC No.26214 (i.e., XYR-19). According to a specific embodiment of the present invention, the proteins of rotavirus group A CGMCC No.26214 of the present invention include one or more of its whole protein, VP4 protein, VP7 protein, VP6 protein, and NSP3 protein. According to a specific embodiment of the present invention, the proteins of rotavirus group A CGMCC No.26214 of the present invention may further include one or more of its VP1 protein, VP2 protein, VP3 protein, NSP1 protein, NSP2 protein, NSP4 protein, and NSP5 protein. According to a specific embodiment of the present invention, the proteins of rotavirus group A CGMCC No.26214 of the present invention include natural proteins and / or recombinant proteins.

[0013] In the present invention, the VP4 protein is a protein translated from the VP4 gene, the VP7 protein is a protein translated from the VP7 gene, the VP6 protein is a protein translated from the VP6 gene, the NSP3 protein is a protein translated from the NSP3 gene, the VP1 protein is a protein translated from the VP1 gene, the VP2 protein is a protein translated from the VP2 gene, the VP3 protein is a protein translated from the VP3 gene, the NSP1 protein is a protein translated from the NSP1 gene, the NSP2 protein is a protein translated from the NSP2 gene, the NSP4 protein is a protein translated from the NSP4 gene, and the NSP5 protein is a protein translated from the NSP5 gene.

[0014] According to a specific embodiment of the present invention, the full gene of rotavirus group A strain XYR-19 is a gene composed of 11 RNA fragments (NSP1, NSP2, NSP3, NSP4, NSP5, VP1, VP2, VP3, VP4, VP6, VP7) contained in XYR-19, which is an important basis for the identification of XYR-19 strains. The full protein of rotavirus group A strain XYR-19 described in the present invention refers to a composition including NSP1, NSP2, NSP3, NSP4, NSP5, VP1, VP2, VP3, VP4, VP6, and VP7 proteins, any two or more of which can form a fusion protein.

[0015] According to a specific embodiment of the present invention, the NSP1 gene sequence of rotavirus group A strain XYR-19 is shown as SEQ ID No.1, and the amino acid sequence of the NSP1 protein encoded thereby is shown as SEQ ID No.12.

[0016] According to a specific embodiment of the present invention, the NSP2 gene sequence of rotavirus group A strain XYR-19 is shown as SEQ ID No.2, and the amino acid sequence of the NSP2 protein encoded thereby is shown as SEQ ID No.13.

[0017] According to a specific embodiment of the present invention, the NSP3 gene sequence of rotavirus group A strain XYR-19 is shown as SEQ ID No.3, and the amino acid sequence of the NSP3 protein encoded thereby is shown as SEQ ID No.14.

[0018] According to a specific embodiment of the present invention, the NSP4 gene sequence of rotavirus group A strain XYR-19 is shown as SEQ ID No.4, and the amino acid sequence of the NSP4 protein encoded thereby is shown as SEQ ID No.15.

[0019] According to a specific embodiment of the present invention, the NSP5 gene sequence of rotavirus group A strain XYR-19 is shown as SEQ ID No.5, and the amino acid sequence of the NSP5 protein encoded thereby is shown as SEQ ID No.16.

[0020] According to a specific embodiment of the present invention, the VP1 gene sequence of rotavirus group A strain XYR-19 is shown as SEQ ID No.6, and the amino acid sequence of the VP1 protein encoded thereby is shown as SEQ ID No.17.

[0021] According to a specific embodiment of the present invention, the VP2 gene sequence of rotavirus group A strain XYR-19 is shown as SEQ ID No.7, and the amino acid sequence of the VP2 protein encoded thereby is shown as SEQ ID No.18.

[0022] According to a specific embodiment of the present invention, the VP3 gene sequence of rotavirus group A strain XYR-19 is shown as SEQ ID No.8, and the amino acid sequence of the VP3 protein encoded thereby is shown as SEQ ID No.19.

[0023] According to a specific embodiment of the present invention, the VP4 gene sequence of rotavirus group A strain XYR-19 is shown as SEQ ID No.9, and the amino acid sequence of the VP4 protein encoded thereby is shown as SEQ ID No.20.

[0024] According to a specific embodiment of the present invention, the VP6 gene sequence of rotavirus group A strain XYR-19 is shown as SEQ ID No.10, and the amino acid sequence of the VP6 protein encoded thereby is shown as SEQ ID No.21.

[0025] According to a specific embodiment of the present invention, the VP7 gene sequence of rotavirus group A strain XYR-19 is shown as SEQ ID No.11, and the amino acid sequence of the VP7 protein encoded thereby is shown as SEQ ID No.22.

[0026] In the present invention, based on the sequence of the whole gene and / or whole protein of the XYR-19 strain, it is also possible to screen and design information containing the XYR-19 strain-specific gene fragments and / or protein (polypeptide) fragments, so as to further develop genetic engineering products such as diagnostic reagents and non-replicative genetic engineering vaccines for the XYR-19 strain. According to a specific embodiment of the present invention, after immunizing an animal with the strain or its specific protein (polypeptide), serum, ascites, etc. can be extracted and prepared by IgG purification to obtain a polyclonal antibody product.

[0027] The VP4 protein genotype is the basis for the classification of rotavirus P type. In general, the P genotype epidemic strains are mainly P[4] and P[8], and the P

[10] genotype is relatively rare, especially the human P

[10] genotype is even rarer. In the present invention, the VP4 gene / protein of strain XYR-19 is specific to the strain. According to the VP4 gene sequence of the strain XYR-19, reassortant viral vaccines and genetic engineering vaccines containing the P

[10] genotype of the strain can be designed. According to the VP4 gene sequence of the strain, the VP4 gene can be cloned, and the VP4 protein can be expressed using a eukaryotic or prokaryotic expression system, and then purified and prepared to obtain recombinant VP4 protein. In addition, the recombinant VP4 protein can be used to immunize animals, and monoclonal VP4 antibody products can be obtained through cell fusion, selective culture, positive clone screening and cloning.

[0028] The VP7 protein genotype is the basis for the classification of rotavirus G type. G3 type rotavirus is one of the current dominant epidemic strains and is a virus seed strain for developing rotavirus vaccines, especially polyvalent rotavirus vaccines. In the present invention, the VP7 gene / protein of strain XYR-19 is specific to the strain. According to the VP7 gene sequence of the strain XYR-19, monovalent or polyvalent reassortant viral vaccines and genetic engineering vaccines containing the G3 genotype of the strain can be designed. According to the VP7 gene sequence of the strain, the VP7 gene can be cloned, and the VP7 protein can be expressed using a eukaryotic or prokaryotic expression system, and then purified and prepared to obtain recombinant VP7 protein. In addition, the recombinant VP7 protein can be used to immunize animals, and monoclonal VP7 antibody products can be obtained by cell fusion, selective culture, positive clone screening and cloning.

[0029] In the present invention, the VP6 gene / protein and NSP3 gene / protein of strain XYR-19 are also specific to the strain. Similarly, monovalent or multivalent reassortant viral vaccines, genetic engineering vaccines, etc. can be designed based on VP6 and / or NSP3, and recombinant proteins can also be produced, and monoclonal or polyclonal antibodies and other products can be developed.

[0030] According to a specific embodiment of the present invention, a reagent for the identification and / or diagnosis of rotavirus XYR-19 can also be designed based on one or more of the full gene, VP4 gene, VP7 gene, VP6 gene, NSP3 gene, full protein, VP4 protein, VP7 protein, VP6 protein, and NSP3 protein of XYR-19. For example, specific primers and / or probes targeting the gene can be designed based on the full gene, VP4 gene, VP7 gene, VP6 gene, or NSP3 gene sequence for the identification and diagnosis of rotavirus.

[0031] Therefore, the present invention also provides the use of the rotavirus group A CGMCC No. 26214 or its specific nucleic acid or its specific protein in one or more of the following aspects:

[0032] Preparation of rotavirus vaccines;

[0033] Preparation of anti-rotavirus antibodies;

[0034] Preparation of detection reagents for identifying rotavirus group A CGMCC No.26214.

[0035] On the other hand, the present invention also provides a rotavirus vaccine, which includes non-replicating rotavirus group A CGMCC No. 26214, rotavirus group A CGMCC No. 26214-specific nucleic acid, rotavirus group A CGMCC No. 26214-specific protein, and / or a specific immunogenic fragment derived from the rotavirus group A CGMCC No. 26214.

[0036] In the present invention, the method for preparing the vaccine can be carried out according to conventional techniques in the relevant field.

[0037] On the other hand, the present invention also provides an anti-rotavirus antibody, which is obtained by immunizing an animal with rotavirus group A CGMCC No. 26214 or a protein specific to rotavirus group A CGMCC No. 26214, and can be a monoclonal antibody or a polyclonal antibody.

[0038] In the present invention, the method for preparing the antibody can be carried out according to conventional techniques in the relevant field.

[0039] On the other hand, the present invention also provides a detection agent or kit for identifying rotavirus group A CGMCC No. 26214, which comprises one or more of the following substances:

[0040] Rotavirus group A CGMCC No.26214;

[0041] Nucleic acid specific to rotavirus group A CGMCC No.26214;

[0042] Specific amplification primers and / or probes for nucleic acid specific to rotavirus group A CGMCC No.26214;

[0043] Rotavirus group A CGMCC No.26214 specific protein;

[0044] Specific binding antibody against the protein specific to rotavirus group A CGMCC No.26214.

[0045] In the present invention, the design of specific amplification primers and / or probes for rotavirus group A CGMCC No. 26214 specific nucleic acid can be carried out by referring to conventional techniques in the relevant field.

[0046] In summary, the present invention provides a human-derived G3P

[10] type human rotavirus strain XYR-19 and its identification method and related applications, and also provides a method for culturing G3P

[10] type human rotavirus using Vero cells as a cell matrix, wherein the method is simple to operate and reduces the risk of contamination; the economic cost of the cultivation is low, and the virus has strong replication ability and good genetic stability; the cultivation and harvesting time is fixed; and the virus harvested by the cultivation method has a high titer and good immunogenicity. The present invention can be applied to the development of human rotavirus vaccines, especially multivalent inactivated human rotavirus injection vaccines, to further provide safer and more effective protection for infants and young children. BRIEF DESCRIPTION OF THE DRAWINGS

[0047] Figure 1 :Morphology of XYR-19 strain under electron microscope.

[0048] Figure 2 : Pathological changes of normal MA104 cells and isolated XYR-19 strains on cells, in the figure a: normal MA104 cells, b: pathological changes of the strains on MA104 cells.

[0049] Figure 3 : Pathological changes of normal Vero cells and isolated XYR-19 strain on cells, in the figure a: normal Vero cells, b: pathological changes of the strain on Vero cells.

[0050] Figure 4 : PAGE genomic electrophoresis of isolated strain XYR-19.

[0051] Figure 5 :Titer of XYR-19 strain on Vero cells. The infectivity titer of the harvested fluids of different generations of XYR-19 strain cultured on Vero cells was tested. The results showed that the titer of the inoculated XYR-19 strain was high, with an average titer of 6.98±0.51LogPFU / ml.

[0052] Figure 6 :The titer of XYR-19 strain cultured on Vero cells at different MOIs. The XYR-19 strain was inoculated into Vero cells at 0.05-0.5 MOI, and the infectious titer was tested after 72 hours of culture. The results showed that the titer of XYR-19 strain inoculated at 0.05-0.3 MOI was high, and the titer increased with the increase of MOI. However, when the MOI exceeded 0.3, the titer did not increase significantly even if the inoculation MOI was further increased. Therefore, the appropriate MOI range for XRY-19 strain culture is 0.05-0.3.

[0053] Figure 7: Growth curve of XYR-19 strain on Vero cells. XYR-19 strain was inoculated into Vero cells at 0.1 MOI, and the infectivity titer was tested after culturing for 24h-144h. The results showed that the virus harvest liquid of about 6.0LogPFU / ml could be harvested after culturing XYR-19 strain on Vero cells for 48h-120h. When the culture time exceeded 120h, the virus titer no longer increased significantly, and even decreased. Therefore, the appropriate harvest time for XRY-19 strain culture is 48h-120h.

[0054] Figure 8 : After mice were immunized with the XYR-19 strain, the IgG antibody titer was tested. After two immunizations, IgG antibodies with a titer higher than 8192 were produced in the mice, proving that the XYR-19 strain has good immunogenicity.

[0055] Fig. 9 : After mice were immunized with the XYR-19 strain, the neutralizing antibody titer was tested. After two immunizations, anti-rotavirus neutralizing antibodies with a titer higher than 128 were produced in the mice, proving that the XYR-19 strain has good immunogenicity.

[0056] Deposit of microorganisms for patent procedures:

[0057] Rotavirus strain XYR-19 of the present invention:

[0058] Deposit date: August 7, 2023;

[0059] Depository: China General Microbiology Center (CGMCC);

[0060] Address of the depository: Institute of Microbiology, Chinese Academy of Sciences, No. 3, Yard 1, Beichen West Road, Chaoyang District, Beijing;

[0061] Deposit number: CGMCC No.26214;

[0062] Classification and nomenclature: Rotavirus A. DETAILED DESCRIPTION

[0063] Before further describing the specific embodiments of the present invention, it should be understood that the scope of protection of the present invention is not limited to the specific embodiments described below; it should also be understood that the terms used in the examples of the present invention are for describing the specific embodiments rather than for limiting the scope of protection of the present invention.

[0064] When embodiment provides numerical range, it should be understood that, unless the present invention indicates otherwise, the two endpoints of each numerical range and any numerical value between the two endpoints can be selected.Unless otherwise defined, all technical and scientific terms used in the present invention are identical with the meanings commonly understood by those skilled in the art.Except the concrete method, equipment, reagent materials used in the embodiment, according to the grasp of prior art by those skilled in the art and the record of the present invention, any method, equipment and material of the prior art similar or equivalent to the method, equipment, reagent materials in the embodiment of the present invention can also be used to realize the present invention.

[0065] Unless otherwise stated, the experimental methods, detection methods, and preparation methods disclosed in the present invention all adopt conventional techniques in the technical field.

[0066] For easier understanding of the present invention, some technical and scientific terms are specifically defined below. Unless otherwise specifically defined herein, all other technical and scientific terms used herein have the meanings commonly understood by those skilled in the art.

[0067] Example 1. Isolation, culture and identification of human rotavirus strain XYR-19

[0068] Obtaining virus samples: Diarrhea fecal specimens from pediatric diarrhea patients in the hospital were collected, resuspended in 0.01M PBS, pH 7.2 solution (Sevier, G4202), centrifuged at 12000g for 20 minutes, and the supernatant was concentrated to 15 times the volume using a 100K ultrafiltration tube (Merck, Amicon Ultra-15), and sterilized and filtered using a 0.22μm filter (Millex, SLGPR33RB), and stored at -20℃ for later use.

[0069] Adaptation of the virus strain to MA104 cells: P64 generation MA104 (preserved and provided by the Molecular Biology Laboratory, Institute of Medical Biology, Chinese Academy of Medical Sciences) cells that had formed a monolayer were digested with 0.25% trypsin-EDTA (Gibco, 25200072). After the cells were digested to form a single cell, they were resuspended in MEM (Central Supply Room, Institute of Medical Biology, Chinese Academy of Medical Sciences, J2023-02-F)-8% BCS (Lanzhou Minhai, 20210214) and diluted to 10 4.0 cells / ml, based on 2×10 5.0 Cells / bottle were inoculated into small square bottles. After 3-4 days of culture at 37℃, MA104 cells grew into a monolayer. 100μl of the diluted solution of diarrhea samples from children infected with rotavirus was inoculated into the cells. Then MEM cell maintenance solution without calf serum was added. The cells were cultured at 37℃ and the cytopathic effect was observed. After 3-4 days of cytopathic effect, the culture was harvested. After the culture was harvested, the MA104 cells were inoculated in the same way for passage or frozen for future use.

[0070] Virus strain culture on Vero cells: P140 Vero cells (preserved and provided by the Molecular Biology Laboratory, Institute of Medical Biology, Chinese Academy of Medical Sciences) that had formed a monolayer were digested with 0.25% trypsin-0.01% EDTA, and the cells were resuspended in MEM-8% BCS and diluted to 10 4.0 cells / ml, based on 2×10 5.0 Cells / bottle are inoculated into small square bottles, cultured at 37℃ for 3-4 days until a dense cell monolayer is formed, and then the virus solution harvested from the original MA104 cells is inoculated at an MOI of 0.1. Subsequently, MEM cell maintenance solution without calf serum is added, cultured at 37℃ for 72h, and the culture is harvested. After the culture is harvested, the Vero cells are inoculated in the same way for passage or frozen for future use.

[0071] Virus strain clone screening: After the virus strain is adaptively cultured on Vero cells, it is purified by plaque cloning twice on Vero monolayer cells, and finally the plaque clone is selected and the clone is continued to grow and pass on Vero cells. Through identification experiments, titer determination, sterility test, mycoplasma test, immunogenicity test, etc., clones with good immunogenicity are screened for use as virus strains for subsequent vaccine development and infection model strains for establishing animal research models.

[0072] In this embodiment, a human rotavirus strain was screened and named XYR-19 in the present invention. The strain has been patented. Deposit date: August 7, 2023; deposit unit: General Microbiology Center of China Microbiological Culture Collection Administration (CGMCC); deposit unit address: Institute of Microbiology, Chinese Academy of Sciences, No. 3, Yard No. 1, Beichen West Road, Chaoyang District, Beijing; deposit number: CGMCC No. 26214; classification name: Rotavirus A group (Rotavirus A).

[0073] The human rotavirus strain XYR-19 of the present invention can be cultured in Vero cells for growth and passage. The specific culture method is as described above. The morphology of the XYR-19 strain can be found in Figure 1 For the pathological changes of normal MA104 cells and the isolated XYR-19 strain on cells, please refer to Figure 2 , where picture a: normal MA104 cells, picture b: pathological changes of the strain on MA104 cells. For pathological changes of normal Vero cells and isolated XYR-19 strains on cells, see Figure 3 , where picture a: normal Vero cells, picture b: pathological changes of the strain on Vero cells. See the PAGE genomic electrophoresis of the strain XYR-19 for Figure 4 .

[0074] The nucleic acid of the XYR-19 virus strain genome was extracted using the Thermo Fisher viral genomic RNA extraction kit, and the viral RNA was reverse transcribed using the TAKARA OneStep RT-PCR kit. 11 pairs of primers for 11 RNA fragments were designed and synthesized using conventional techniques based on the full gene sequence of the group A rotavirus G3 genotype, and 11 cDNA gene fragments were obtained by segmentation using the RT-PCR method, cloned into the pMD19-T vector, and sequenced one by one. Thus, the full gene sequence of the XYR-19 virus strain was obtained. NSP1 gene (SEQ ID No.1):

[0075] ATGGCAACCTTTAAGGATGCTTGTTTCATTATAGAAGGATTACAAAACTAAATAGAGAACTACTGAGAATTGGAGCG

[0076] AACTCAGTATGGACTCCAGTCTCTTCGAATAAAATTAGAGGGTGGTGTATTGAATGTTGTCAACTGACTGAATTGACC

[0077] TTTTGTCACGGATGTTCATTGGCTCACGTTTGTCAGTGGTGCATTCAAAACAAACGTTGTTTCTTAGACAATGAACCA

[0078] CATCTTTTAAAACTGAGGACCTTTGAATCTCCAATAACAAAGGAAAAATTGCAATGCATTATTGATCTATATAATTTG

[0079] TTATTCCCAATTAGTCCTGGTATTATTAACAAATTCAAAAAGGCAGTTAAACAGAGAAAATGTAGAAATGAACTTGAC

[0080] AAATCATGGTATAATCAATTGTTACTTCCAATTACTTTGAATGCTGCAGTTTTTAAATTTCATTCAAGAGAAGTTTAC

[0081] GTTTTTGGGTTTTACGAGGGATCATTATCATGTACAGATTTACCATATAGACTTGTAAATTGCATTGACTTATATGAT

[0082] AGATTATTGTTAGATCAAATAAACTTTGAAAGAATGAGTTCTCTTCCAGACAATTTACAATCCATCTATGCAAACAAA

[0083] TATTTTAAATTGAGTAGACTTCCTTCAATGAAATTAAAGCAAATCTATTACTCGGATTTCTCCAAACAAAATCTGATT

[0084] AATAAGTATAAGACTAAGAGTCGCATAGTGCTTAGAAATCTCACCGAATTCACCTGGGCTTCTCAAACTGATTTGCAT

[0085] CATGATCTACTCAATAATAAAGATAAAATACTTGCGGCTTTATCAACATCATCATTAAAGCAATTTGAAACGCATGAT

[0086] TTAAATTTGGGGAGAGTGAAAGCTGACATTTTTGAGCTTGGACATCATTGTAAACCAAATTATATCTCGTCAAATCAT

[0087] TGGCAGCCAGCATCAAAAATTTCTCAATGCAAATGGTGTAATGTAAAATATGCATTCAGAGATATGGATTGGAAAATG

[0088] GAATCAATGTATAATGAACTTTTAAGCTTCATCCAATCCTGTTATAAAAGTAATGTTAATGTAGGGCATTGTAGTTCA

[0089] GTTGAAAGTGCTTATCCACTAGTCAAAGATATACTCTGGCATTCAATTACCAAATACATTGATCAAGCTATTGAAAAA

[0090] TTATTTAATGTAATGAATCCAACGCAAGTAAATGATCAGCAAGTAATTAGTTTTCACTGGCAAATAGACATCGCTTTA

[0091] TACATGCACATTAAAATGATACTAAAAACTGAAGCTCTTCCATTTACTTTTACACTGGACCAGTTTAACTCTATAATT

[0092] AAAGGAATTGTGAACCAAYGGTGTGATGTTACTGAATTAGATCTGCTACCGTTATGCACTGAACAAACTGACAAATTA

[0093] GTTAAACTAGAAGAAGAAGGAAAGCTATCTGAAGAGTATGAGCTTCTAATCTCAGATTCTGAAGATGATGACTAANSP2 gene (SEQ ID No.2):

[0094] ATGGCTGAGCTAGCTTGCTTTTGTTACCCTCATCTAGAGAATGATAGCTATAAGTTTATTCCATTTAATAGTTTAGCA

[0095] ATTAAGTGTATGTTGACAGCTAAAGTGGACAAGAAAGATTTAGACAAGTTTTATAATTCAATAATCTACGGAATTGCG

[0096] CCACCTCCACAATTTAAAAAACGTTATAACACTAATGATAATTCAAGAGGAATGAACTTTGAAACACAGATGTTCACT

[0097] AAGGTGGCAATGTTGATTTGCGAAGCTCTGAATTCACTAAAGATCACACAGACAGACGTCGCGAACGTATTATCTCGT

[0098] GTTGTTTCAGTTCGACATTTAGAAAACTTGGTACTAAGAAAAGAAAATCATCAAGATGTGCTCTTTCATTCAAAAGAT

[0099] CTACTAATTAAATCAGTGCTCATAGCTATTGGACAATCGAAAGAGATTGAAACTACAGCTACAGCTGAAGGAGGAGAA

[0100] ATTGTGTTTCAGAACGCTGCTTTTACTATGTGGAAATTGACCTATCTTGATCATCAACTAACGCCAATACTTGATCAG

[0101] AACTTTGTTGAATATAAAGTTACATTGAATGAAGACAAGCCAATTTCAGATGGGCATGTAAAAGAACTAGTTGCTGAG

[0102] CTTCGCTGGCAATATAATAAATTTGCAGTTATTACACACGGAAAAGGACATTATAGAGTAGTTAAGTATTCATCAGTT

[0103] GCCAACCACGCAGACAGAGTTTATGCTACTTTTAAGAATAATAATAAATCTGGAATTTCATCTGACTTCAATCTTCTC

[0104] GACCAAAGAATAATTTGGCAAAACTGGTATGCATTTACATCTTCAATGAAACAAGGGAATACTCTCGATGTTTGCAAA

[0105] AAACTACTCTTTCAAAAGATGAAGCAAGAAAAGAATCCATTCAGAGGTCTGTCAACTGATAGGAAGATGGATGAAGTC

[0106] TCTCAAGTAGGCGTTTAATTCGCT

[0107] NSP3 gene (SEQ ID No.3):

[0108] ATGCTCAAGATGGAGTCTCAGCAGCAGATGGCTTCCTCTATTATTAATTCTTCTTTTGAAGCTGCAGTAGTTGCTGCA

[0109] ACTTCTACTCTTGAATTAATGGGCATTCAATATGATTACAATGAGGTATATACTAGAGTGAAGAGTAAGTTTGATTTT

[0110] GTTATGGATGACTCTGGTGTAAAGAACAATTTAATGGGTAAGGCAATTACCATTGACCAAGCTTTGAATGGGAAATTT

[0111] GGCTCAGCAATTAGGAATAAAAATTGGATGACTGACTCTCGAACCGTGGCTAAGCTGGATGAGGATGTGAACAAAATTG

[0112] AGAATGATGTTATCGTCAAAAGGGATTGATCAAAAAATGAGAGTGCTGAATGCTTGTTTTAGCGTTAAAAGAGTACCT

[0113] GGAAATCATCATCTATAATAAAATGTACTAGGCTAATGAAAGACAAATTAGAACGCGGCGAAGTCGAAGTTGATGAT

[0114] TCTTTTGTTGAGGAAAAAATGGAAATAGACACAATTGACTGGAAATCAAGATATGAACAACTAGAAAAAAGATTCGAG

[0115] GCATTAAAGCATCGGGTTAATGAGAAATATAAATATTGGGTTATTAAAGCGAGAAAAGTAAATGAAAATATGAATTCC

[0116] CTTCAAAACGTGATCTCTCAACAGCAAGCACATATTAATGAATTGCAAATGTATAATAATAAATTAGAACGTGATTTA

[0117] CAATCGAAGATTGGATCAGTTGTGTCATCAATAGAATGGTATTTAAGGTCAATGGAACTATCTGATGATGTTAAATCA

[0118] GACATTGAGCAACAGTTAAATTCAATAGATCAATTGAATCCAGTTAATGCAATGGATGATTTCGAATCAATACTTCGT

[0119] AATTTAATTTCTGATTATGATAGATTGTTTCTAATGTTTAAAGGACTATTGCAGCAATGTAATTATACTTGCACTTAT

[0120] GAATAATTGAATGAATTAATTAACGACATTACCATCTACACATGACCCTCTATGAGCACAATAGTAAAANSP4 gene (SEQ ID No.4):

[0121] GTTCCGAGAGAGCGCGTGCGGAAAGATGGACAAGCTTACCGACCTCAATTACACATTGAGTGTAATCACTCTAATGAA

[0122] TGAGACGTTACATACTATAATGGAGGATCCTGGAATGGCGTATTTTCCATATATTGCTTCTGTTCTAATTGTGTTGTT

[0123] TACACTGCATAAAGCTTCGATTCCTACCATGAAAATTGCCCTTAAAACATCAAAATGTTCATATAAAGTAGTTAAATA

[0124] TTGTATTGTATCAATATTTAATACTCTACTGAAATTAGCTGGGTACAAGGAACAAATTACTACTAAAGATGAAATTGA

[0125] GAAACAAATGGACAGAGTTGTAAAAGAGATGAGACGTCAACTGGAAATGATTGATAAACTAACTACTAGAGAAATAGA

[0126] ACAGGTTGAGTTACTTAAACGAATTCATGACATGCTAATAATTAAACCAGTTGATAAAGTTGATATGTCGCAAGAATT

[0127] CAATCAGAAACATTTTAAAACGCTAAATGAATGGGCTGAAGGAGAAAATCCATACGAACCAAAAGAAGTGACTGCATC

[0128] TTTGTGAGAGGTTGAGCTACCGTCGTCTGTCTACGGAAGCGACGGAGTTCTTAACAGTAAGCCCCATCGGACCTGATG

[0129] ATTGGTTGAGAAGCCACAACCAGTCATATCGCGTGTGACCTAGTCTTAATCCCGTTTAACCAATCCAGCCAGTGCTGG

[0130] ACGTTAATGGAAGGAACGGTC

[0131] NSP5 gene (SEQ ID No.5):

[0132] CAGTGATGTCTCTCAGTATTGACGTGACAAGTCTTCCTTCTATTTCTTCTAGTATTTATAAACATGAATCATCTTCAA

[0133] CAACGTCAACTCTTTCTGGAAAATCTATTGGTAGGAGTGAACAGTACGTTTCACCGGATGCAGAAGCATTCAATAAAT

[0134] ACATGTTGTCGAAGTCTCCAGAGGATATTGGACCATCTGATTCTGCTTCGAACGATCCACTCACCAGTTTTTCGATTA

[0135] GATCGAATGCAGTTAAGACAAATGCAGATGCTGGCGTGTCTATGGATTCATCGACGCAATCACGACCTTCAAGCAACG

[0136] TTGGATGTGATCAAGTGGATTTCTCCTTGAGTAAAGGTATTAAAGTCAACGCTAATTTAGATTCTTCCATTTCAGTGT

[0137] CAACAGTTTCTAAAAAGGAGAAGTCCAAATCAGACCATAAAAGTAGGAAACACTACCCAAGGATTGAAGCAGATTCCG

[0138] ATTCAGATGAATACGTATTGGATGATTCTGATAGTGATGATGGGAAGTGTAAGAACTGTAAATATAAGAAAAAGTACT

[0139] TTGCACTCAGAATGAGAATGAAACAAGTCGCAATGCAATTGATTGAAGATTTGTAAGTCTGACCTGAGAACTCACTAG

[0140] GGAGCTCCCCACTCCGTTTT

[0141] VP1 gene (SEQ ID No.6):

[0142] ATGGGGAAGTACAATCTAATCTTGTCAGAATATTTATCTTTTATTTATAATTCACAATCTGCTGTACAAATTCCAATT

[0143] TATTATTCTTCCAATTCAGATCTAGAAAAAAGATGTATAGAATTTCATTCAAAATGCTTAGAGAATTCAAAAAAAGGA

[0144] TTATCTTTAAAAAATGTTTTTGTAGAATATAAAGATGTCATTGAGAATGCAACGTTACTATCAATACTATCGTATTCA

[0145] TATGATAAGTATAACGCAGTAGAAAGAAAGCTGGTGCATTATGCAAAAGGTAAACCTTTAGAAGCTGATCTAAATGCG

[0146] AATGAGTTAGATTATGAAAATAATAAATTGACTAGTGATCTATTTCCAACTGCTGAAGAATATACTGATTCACTAATG

[0147] GATCCAGCAATACTGACATCGCTATCTTCAAATTTAAATGCAGTTATGTTTTGGTTAGAGAAGCATGCAAATGACACT

[0148] GCAGAAAAAGCTAAAATTTATAAGAGAAGGCTTGATCTATTTACAATTGTAGCTTCAACAGTGAATAAGTACGGAGTA

[0149] CCCAGACACAATGCAAAATATAGATATGAATACGATGTAATGAAAGATAAGCCATATTATTTAGTGACGTGGGCGAAT

[0150] TCATCAATTGAGATGTTAATGTCAGTATTTTCACATGAAGATTATTTAATTGCGAAGGAGTTAATAGTTCTTTCATAT

[0151] TCAAATAGATCCACTTTAGCCAAACTCGTCTCATCGCCAATGTCAATTTTGGTCGCGTTAGTGGATATAAACGGTACC

[0152] TTCATTACTAATGAAGAACTGGAATTAGAGTTTTCTAATAAATATGTTAAAGCAATTGTTCCAGATCAAACTTTCGAT

[0153] GAATTGAAAGAGATGCTTGATAATATGAAGAAAGCTGGACTAGTTGATATACCAAAAATGATACAGGACTGGTTGGTG

[0154] GATTGTTCAATTGAAAATTTTCCATTAATGGCAAAAATTTATTCTTGGTCTTTTCATGTAGGGTTCAGAAAACAGAAA

[0155] ATGTTGGATGCTGCTTTAGATCAATTAAAAACTGAATACACTGAAGACGTTGATGACGAAATGTATAGAGAGTATACT

[0156] ATGTTAATTAGAGACGAAGTTGTAAATATGTTAGAAGAGGCAGTTAAACATGATGATCATCTTCTCCAAGATTCTGAG

[0157] TTAGCAGGGCTACTATCAATGTCATCAGCATCAAATGGTGAGTCACGACAACTGAAGTTCGGCCGAAAAACCATCTTT

[0158] TCTACAAAAAAGAATATGCACGTAATGGATGACATGGCTAACGGGAGATACACGCCAGGAGTAATCCCACCAGTTAAT

[0159] GTTGATAAACCAATTCCATTAGGAAGACGAGATGTTCCGGGCCGACGTACGAGAATAATTTTTATATTACCATATGAG

[0160] TATTTCATTGCTCAACACGCAGTCGTTGAAAAGATGTTAATTTATGCAAAGCATACGAGAGAATATGCTGAATTTTAT

[0161] TCACAGTCTAATCAGTTACTTTCTTATGGAGATGTTACTAGATTTTTATCAAATAATGCTATGGTATTATACACTGAT

[0162] GTATCACAGTGGGACTCATCTCAACATAACACACACAGCCATTTAGAAAAGGGATAATTATGGGATTAGATATGTTAGCT

[0163] AATATGACTAATGACGTAAAGGTAATACAAACACTACATTTATATAAGCAGACGCAGATTAATTTAATGGATTCATAT

[0164] GTACAAATACCGGATGGAAATGTAATTAAAAGATACAATATGGAGCAGTCGCATCAGGTGAAAAACAGACGAAAGCT

[0165] GCTAATTCTATAGCCAATCTAGCATTAATTAAAACAGTTCTATCGCGTATAGCAAATAAATATTCATTTGTAACTAAA

[0166] ATAATCCGAGTTGATGGAGACGATAACTATGCAGTTTTACAGTTTAATACTGAAGTAACCAAACAGATGGTACAAGAT

[0167] GTATCAAATGATGTCAGAGATACTTAGCACGAATGAACGCTAAAGTAAAGGCTTTGGTTTCAACGGTTGGGATAGAG

[0168] ATCGCTAAACGCTATATCGCTGGTGGAAAAAATTTTTTTAGAGCTGGTATAAATTTGCTAAATAATGAAAAACGAGGA

[0169] CAGAGTACACAATGGGACCAGGCAGCCGTTCTATATTCAAATTACATTGTTAATATAGGTTAAGAGGTTTTGAGACTGAT

[0170] AGAGAATTCATATTAACGAAAATTATGCAAATGACATCAGTAGCTATAACTGGATCGCTTAGATTATTCCCATCAGAA

[0171] AGAGTTCTAACGACTAACTCTACATTTAAAGTTTTTGATTCAGAAGATTTCATAATTGAATATGGTACTACAGACGAT

[0172] GAGGTGTATACAGAGAGCGTTTATGTCATTATCAAGCCAGAAGTCAGGAATAGCAGACGAGATTGCAGCATCGCAA

[0173] ACATTTAAAAAATTATGTATCCAAACTTTCAGATCAATTGTTAGTATCAAAAAACGCAATCGTTTCAAGAGGTATAGCA

[0174] TTAACTGAGAAAGCAAAGTTAAACTCGTATGCACCTATTTCTTTAGAAAAGCGTCGTGCACAAATTTCTGCCCTGTTA

[0175] ACAATGTTACAGAAGCCAGTGACATTTAAATCGAATAAGATAACTATTAATGATATTTTACATGACATTAAACCATAC

[0176] TTTGTAATGAGTGAAGCTAATCTGCCAATGCAATATCAAAAATTTATGCCAACTTTGCCTACCAATGTTCAGTATATA

[0177] ATACAGTGCATTGGATCAAGAACTTATCAGATTGAAGATGATGGATCTAAATCAGCCATTTCAAAATTGATATCGAAG

[0178] TACTCAGTATATAGACCATCAATAGAAGAACTGTATAAAGTAATATCACTTCACGAACAAGAAATCCAGCTTTATCTA

[0179] GTATCACTAGGAGTTCCTAAGATTGATGCTGATACTTACATTGGATCAAAAATTTATTCACAGGATAAGTACCGCATA

[0180] CTAGAATCATATGTGTATAACTTATTATCTATAAATTATGGTTGTTATCAACTTTTTGACTTTAATTCACCAGATCTA

[0181] GAGAAACTAATAAGGATTCCATTTAAAGGAAAAATACCAGCTGTGACGTTTATTCTACATTTATACGCCAAATTAGAA

[0182] ATTATTAACTATGCCATAAAGAATGGTTCATGGATCAGCTTATTTTGTAACTATCCAAAGTCTGAAATGATTAAACTT

[0183] TGGAAGAAAATGTGGAACATAACTTCATTGAGATCTCCCTATACCAATGCAAACTTCTTTCAAGATTAGAGCVP2 gene (SEQ ID No.7):

[0184] GGGGAAAAAAAGGGAATGCCGTACAGAAAACGTGGAGCGCGCCGTGAGACGATTTTAAAACAAGATGATCGAATGCAG

[0185] GAAAAAAGAAGAGATAAAAACGTAAATGGTAATGTTGAAAATAAAAATGTTACAAAAACTCAATTGTCAGAAAAAGTA

[0186] TTATCTCAAGGAAGAAGTAATTACAGATAATCAAGAGGAAATTAAAATAGCTGATGAAGTTAGAAAATCTAGTAAA

[0187] GAAGAGTCAAAACAACTATTGGAGGGTTCTAAAAACTAAAGAAGAACATCAGAAAGAAGTTCAATATGAAATATTACAA

[0188] AAAACAATACCTACTTTTGAACCAAGAATCTATACTAAAGAAACTAGAAGATATTAAACCAGAACAAGCCAAGAAA

[0189] CAAACTAAGCTGTTCAGAATATTTGAACCTAAGCAATTACCAATATATAGGGCAAACGGAGAAAAAGAATTACGTAAC

[0190] AGATGGTATTGGAAGTTAAAACGAGACACTTTGCCAGATGGAGATTATGATGTGAGAGAATATTTTTTGAATCTATAT

[0191] GATCAAGTACTAACTGAAATGCCAGATTACCTACTACTTAAAGACATGGCTGTTGAAAATAAAAACTCTAGAGATGCA

[0192] GGCAAAGTCGTTGACTCTGAAACTGCAGCCATTTGTGATGCAATTTTCCAAGATGAAGAAACTGAAGGTGTAGTAAGA

[0193] AGATTCATAGCAGAAATGAGACAAAGAGTACAAGCTGATCGAAACGTAGTTAATTATCCATCAATACTACATCCAATC

[0194] GATCATGCGTTCAATGAGTACTTTTTGCAGCATCAATTAGTCGAACCATTGAATAATGATATAATATTTAACTATATA

[0195] CCTGAAAGAATACGGAATGACGTAAACTATATACTGAACATGGATCGAAACCTACCTTCAACAGCTAGATACATCAGA

[0196] CCAAATTTACTTCAAGATAGACTTAATTTGCATGACAACTTCGAATCTTTATGGGATACTATAACTACATCAAACTAT

[0197] ATCTTAGCTAGATCGGTTGTACCAGATCTTAAGGAACTAGTATCCACAGAAGCTCAAATACAGAAAATGTCACAGGAT

[0198] TTGCAGTTAGAAGCACTAACAATTCAGTCAGAAACGCAATTTTTAACAGGCATCAATTCACAGGCAGCTAATGACTGC

[0199] TTTAAGACGTTAATTGCTGCTATGCTTAGCCAACGTACTATGTCTTTAGATTTCGTCACTACAAATTACATGTCATTA

[0200] ATTTCAGGAATGTGGTTACTAACGGTTATACCTAATGATATGTTCATACGTGAATCCTTAGTGGCATGTCAGTTGGCA

[0201] ATAATTAACACCATCGTATACCCAGCTTTTGGAATGCAGAGAATGCATTATAGAAATGGTGATCCCCAAACTCCTTTT

[0202] CAGATCGCTGAACAACAAATTCAAAACTTTCAAGTAGCCAATTGGCTACATTTCGTCAACAATAATCAATTTAGACAA

[0203] GTAGTAATTGACGGAGTATTAAACCAAGTTCTGAATGATAACATAAGGAACGGCCATGTAGTTAACCAATTGATGGAA

[0204] GCTTTGATGCAATTGTCACGACAGCAATTTCCAACTATGCCAGTGGATTACAAAAGATCGATACAGAGAGGAATTCTA

[0205] CTTCTATCGAATAGATTGGGACAATTAGTTGACTTAACTAGACTATTGGCATATAATTATGAAACTCTAATGGCGTGT

[0206] ATTACCATGAATATGCAACATGTACAAACTCTAACTACTGAAAAGTTGCAATTAACATCAGTTACTTCCTTATGCATG

[0207] CTAATAGGAAATGCTACAGTTATACCAAGTCCACAAACATTATTTCATTATTATAATGTCAATGTTAACTTCCACTCA

[0208] AATTATAATGAAAGAATAAATGATGCAGTAGCAATCATAACCGCTGCAAATAGGTTGAACTTGTATCAAAAAAAGATG

[0209] AAGTCGATAGTTGAAGATTTCTTAAAGAGACTGCAAATATTCGATGTTTCTAGAGTTCCAGATGATCAGATGTATAGA

[0210] CTCAGAGATAGATTGAGATTACTTCCAGTTGAGATTAGAAGGTTGGACATTTTTAATTTAATATTGATGAACATGGAA

[0211] CAGATCGAACGTGCGTCAGATAAAATTGCTCAGGGAGTGATTATAGCCTATAGAGATATGCAGTTAGAGAGAGATGAA

[0212] ATGTATGGCTACGTTAACATAGCTCGTAACTTAGATGGTTTTCAGCAGATAAATTTAGAAGAGTTGATGAGGACAGGA

[0213] GATTATGCACAAATTACTAACATGCTACTAAATAATCAGCCAGTGGCATTAGTAGGAGCATTGCCATTCATAACAGAC

[0214] TCATCAGTTATATCATTGATAGCTAAATTAGACGCTACCGTCTTTGCACAAATTGTTAAACTTAGAAAGGTTGACACT

[0215] TTAAAACCAATACTGTATAAAATAAATTCCGATTCAAATGATTTTTATCTTGTAGCAAATTATGATTGGGTTCCAACA

[0216] TCTACAACAAAAGTCTATAAGCAAGTACCACAACAATTTGATTTTAGAGCATCTATGCACATGCTAACGTCCAATTTG

[0217] ACTTTCACTGTATATTCCGATCTTCTTGCATTCGTTTCAGCAGATACTGTTGAACCAATTAACGCTGTTGCGTTTGAT

[0218] AACATGCGCATCATGAGCGAACTGTAA

[0219] VP3 gene (SEQ ID No.8):

[0220] ATGAAAGTGCTAGCTTTAAGACACAGTGTGGCTCAGGTATATGCAGACACTCAAGTCTATACTCACGATGATACCAAA

[0221] GACAGTTACGAAAATGCGTTTCTTATATCTAATCTTACAACACATAACATCTTATATTTAAATTATAGTACTAAAACA

[0222] CTTGAAATATTAAATAAATCAGGGATTGCAGCCGTCGAGATTCAATCTTTAGAAGAACTGTTCACTCTAATTAGATGC

[0223] AATTTTACTTATGATTATGAAAACAATATAATCTATTTACATGATTACTCTTTACTACACCAATAATGAAATAAGGACG

[0224] GATCAACATTGGGTTCAAAAAACTGACATTGAAGAATATTGTTACCGGGCTGGAAATTGACATATGTAGGGTACAAC

[0225] GGAAACGACACCAGAGGACACTATAATTTCTCATTCACATGTCAGAATGCTGCAACCGATGATGATTTAATAATAGAA

[0226] TATATTTATTCTGAAGCATTAGATTTCCAAAATTTCATGTTAAAGAAAATTAAAGAAGGATGACTACCTCTTTACCG

[0227] ATAGCACGCTTATCAAATAGGGTTTTTAGAGATAAACTATTCCCGTTATTAAGTAAGAAACATCAACGTATAGTGAAC

[0228] GTCGGACCTAGAAATGAATCAATGTTTACCTTCTTAAATTTTCCATCTATTAAACAATTTTCAAATGGACCATATTTA

[0229] GTTAAGGATACTATTAAATTAAAACAAGAACGATGGTTAGGGAAGCGGATATCACAGTTTGACATCGGGCAATACAAA

[0230] AACATGATGATGTCATAACAACTGTGTATCACTATTACAATTTATATCAGAAGAAGCCTACTATATATATGGTCGGT

[0231] TCAGCTCCTTCATATTGGATTTACGACGTCAAACAGTACTCTGATTTCATGTTTGAAACTTGGGATCCACTTGACACT

[0232] CCGTATTCATCAGTACATCACAGAGAGTTGTTTTTTGAAAAGGACATAGTTAAATTAAAGGATGATTCTATATTATAT

[0233] ATTGATATTAGAACTGATCGTGGAAACATGAATTGGAAAGAGTGGAGAAAGATAGTTGAGACACAAACCATTAACAAT

[0234] CTCAAACTTGTATACCAATATTTAGCCAGTGGTAAGTCGAAAGTATGTTGTGTAAAAATGACAGCTATGGATTTAGAG

[0235] CTTCCTATATCTGCGAAACTATTACATCATCCAACGACTGAGATTCGATCAGAATTTTATTTGCTTTTAGATATCTGGGAC

[0236] GTTAGTAATACCAAACGATTCATTCCAAARGGAGTACTATACTCATTTATAAATAATGTTGTTACTGGAAACGTATTTATA

[0237] CAACCACCATTTAAAATCAAAACGTCTAAGAATGATTACATTGTAGCGTTATATGCATTGTCGAATGATTTCAACGACAGA

[0238] ACAGATGTAGTTAACTTAATTAATAATCAGAAACAGTCACTCATAACTGTAAGAATTAATAATACGTTCAAGGATGAACCA

[0239] AAAGTAGGATTTAAAAATATATATGATTGGACTTTTCTACCGACGGATTTTAGCACAACTAATGCTATTGTAACTTCATAC

[0240] GACGGATGCTTAGGTATGTTTGGRTTGTCAATATCTTTAGCTTCCAAACCGACAGGAAAATAATCATCTATTTATTTTGAGT

[0241] GGAACTGATAAGTACTATAAATTAGACCAATTTGCAAATCATACTGGTATTTCGAGAAGGTCACATCAAGTTAGATTTTCA

[0242] GAATCCGCTACATCGTATTCAGGTTATATATTTCGAGATTTATCTAATAATAATTTTAATTTAATTGGAACTAATGTAGAG

[0243] AATTCAGTTTCAGGACATGGTGTATAATGCATTAATTTATTATATAGATAATTATTCTTTTGATTTAAAAAGATGGATATAT

[0244] CTACATTCAATAGAGAAGGCAGACATAGAAGGTGGGAGATATTATGAACATGCTCCAATAGAATTGATTTATGCATGCAG

[0245] ATCAGCGAAAAGAGTTCGCCTCATTGCAAGATGACCTTTACTGTATTACGTTATGCCAATGAAATCGAACGCTATAATAAATAA

[0246] AGTGTACAGTATAACATACGCAGACGATCCAAATTATTCATAGGTATCAAGTTCAAACATATTCCCTATAAGTATGACGT

[0247] TAAGATTCCACACTTGACATTTGGAGTATTGTTTATTTCAGATAATATGATTCCAGATGTGGTAAGGATTATGAAGGATAT

[0248] GAAGAAAGAGTTATTTGAGATGGACGTAACTACCAGTTATACGTACATGCTATCTGATGGGATATATGTGGCTAATGTTAG

[0249] TGGAGTCTTAGCGGCGTATTTTAAAATGTACAATTTATTTTATAAAAGCCAAATCACATTTGGTCAATCTAGAATGTTTAT

[0250] TCCACATATAACACTAAGTTTTAGTAATAACAAAACAGTAAGAATAGAAACTACTGAGCTAAAAATCAGTTCAATATA

[0251] TCTAAGAAAAATTAGGGGAGATACGGTGTTTGATATGTCTGAGTGAGCTAGAAACTTAACACACTVP4 gene (SEQ ID No.9):

[0252] ATGGCTTCGCTCATTTACAGACAGTTACTTACTAATTCTTATACAGTAGATTTATCCGATGAAATTGAAAGTATTGGA

[0253] TCTGAGAAAAACCAAAATGTAACGATAAACCCTGGACCGTTTGCACAAACCGGGTATGCACCAGTTAATTGGGGACCA

[0254] GGAGAAGTGAATGACTCTACCACTGTTGAACCAACATTAGATGGTCCTTATCAGCCAACAAGCTTCAATCCACCAGTT

[0255] AACTACTGGATGCTTTTAGCTCCGCTGAACGCGGGAGTAGTTGTTGAAGGGACCAATAATACCAATCGTTGGTTAGCT

[0256] ACCATTTTAGTAGAACCAGGAGTGGCGTCGACAACGAGGACATACACATTATTTGGAATACAAGAACAGATTACTGTA

[0257] GAGAATGGTTCAAATACAAAGTGGAAGTTCATAGATTTAATGAAAACTACGTCATCAGGAACATACACTCAACATTCT

[0258] CCATTATTATCAGAGCCAAAACTATATGGTATAATGAAGCACGGTGGTCAGCTCTGGACTTATGATGGAGAGACTCCA

[0259] AATGCAATCACAAACGGTTATTCTACTACTAATTATGATTCAGTCAATATGACTTCATTCTGCGATTTCTATATCATA

[0260] CCTAGATCTCAAGAATCTGTATGTACTGAATACATTAATAATGGGTTACCACCAATGCAGAATACTAGGAACATTGTT

[0261] CCAGTTTCAATTTCCTCACGTAACATTATACATCAAAGGGCACAGGCTAATGAAGATATTGTAGTATCAAAAACTTCG

[0262] CTTTGGAAAGAGATGAAATATAATAGAGATATTACGATCAGATTTAAATTTGCTAACGCAATAATTAAATCAGGTGGA

[0263] TTGGGATATAAATGGTCAGAAATTTCTTTCAAACCAGCGAACTATCAATATACATATATTAGAGATGGTGAAGAAGTG

[0264] ACTGCGCATACAACATGTTCTGTGAACGGAGTGAACGATTTTAGCTTTAATGGTGGATCGTTACCAACCGACTTTGTT

[0265] ATATCACGATATGAAGTAATAAAAGAAAATTCCTATGTTTATRTAGACTATTGGGATGACTCGCAGGCGTTCAGGAAC

[0266] ATGGTATATGTGAGATCGCTAGCCGCGGATTTAAATGATGTATTGTGCACCGGTGGTGACTACAGTTTCGCATTACCA

[0267] GTCGGACAATGGCCGGTGATGACAGGTGGTGCTGTTTCATTGCATTCAGCTGGGGTTACATTATCAACGCAATTTACT

[0268] GACTTTGTTTCGCTTAACTCACTTAGATTCAGGTTCAGGTTAACAGTTGAAGAACCATATTTCTCTATTACTAGAACT

[0269] CGTGTAACTAGATTGTACGGACTACCRGCTGCAAATCCAAATAATAATAAAGAGTATTATGAGGTCGCTGGAAGGTTT

[0270] TCATTGATATCATTAGTACTATCCAACGACGACTATCAGACGCCAATTGCGAATTCCGTCACAGTTAGACAAGATTTA

[0271] GAAAGACAATTAGGGGAATTGAGAGAAGAATTCAATGCACTGTCACAAGAAATTGCAATGTCACAATTGATTGACTTA

[0272] GCGTTACTTCCGCTAGATATGTTTTCAATGTTTTCAGGCATTAAGAGTACGATAGACGCGGCGAAATCAATGGCGACT

[0273] AATGTCATGAAAAAATTCAAAAAATCAGGATTAGCTACATCCGTTTCTACCTTAACTGACTCACTATCAGATGCAGCG

[0274] TCCTCAATTTCCAGAGGTTCGTCACTTAGATCTGTAGGATCATCAGCTTCGGCTTGGACTGATGTATCAACACAGTTG

[0275] ACTGATGTTTCAAGTACCGTAAACACTATATCAACACAAACTTCTACTATCAGCAGACGTCTGAGACTAAAAGAAATC

[0276] GCTACACAAACTGAAGGTATGAATTTTGATGACATTTCTGCTGCCGTTCTAAAAACTAAGATTGACAAGTCAACACAA

[0277] ATAGCACCAGCTACGTTACCCGATATTGTTACTGAAGCATCTGAAAAATTCATTCCTAACAGAGCATATAGAGTAATA

[0278] AACAACAATGAAGTATTGGAAGCTGGTACTGATGGTAGATTTTTCGCTTATAGAGTAGAGACATTTGAAGAAATACCA

[0279] TTCGATGTACAAAAGTTCGCTGATCTAGTGACTGATTCGCCAGTAATCTCAGCTATTATTGATTTCAAAACATTAAAG

[0280] AATCTGAACGATAATTATGGAATATCTAGAGAGCAGGCATTTAATCTTCTACGTTCTGATCCTAGAGTACTACGAGAA

[0281] TTCATTAATCAAGATAATCCAATAATTAGAAATAGAATCGAACAATTGATACTGCAATGTAGATTGTAAVP6 gene (SEQ ID No.10):

[0282] TAGAGACAAAATTGTCGAAGGCACATTATACTCAAATGTCAGTGACCTAATACAACAATTTAACCAAATGATAATTAC

[0283] AATGAATGGCAATGAATTTCAAACGGGTGGAATTGGTAATTTACCAGTTAGAAATTGGAATTTTGATTTTGGCTTGCT

[0284] TGGCACAACATTGCTTAATCTTGACGCCAATTATGTCGAAACTGCTCGAACCACAATTGAATATTTCGTTGACTTTGT

[0285] AGACAACGTTTGTATGGATGAGATGGCTAGAGAATCGCAGCGGAATGGAATAGCTCCTCAGTCAGATGCTTTAAGAAA

[0286] ATTGTCAGGAATAAGATTTAAAAGAATTAACTTTGATAATTCATCAGAATATATAGAGAATTGGAATCTACAGAGCAG

[0287] AAGACAAAGAACTGGATTTACTTTTCATAAACCAAACATTTTTCCGTACTCAGCATCATTTACCCTGAATAGGTCTCA

[0288] ACCGCAACATGATAATTTAATGGGTACTATGTGGCTAAATGCAGGATCAGAAATTCAAGTTGCGGGATTTGATTACTC

[0289] TTGTGCTATCAACGCTCCAGCCAATACTCAACAGTTTGAACATATTGTACAATTGCGCCGTGTTCTGACAACAGCAAC

[0290] TATCACACTCCTTCCAGATGCAGAAAGATTCAGCTTTCCAAGAGTAGTTAATTCCGCTGATGGCGCTACAACGTGGTA

[0291] TTTCAATCCCGTAGTACTGCGACCTAATAATGTTGAAGTTGAATTTCTATTGAATGGCCAAATAATTAATACGTATCA

[0292] AGCTAGATTTGGTACAATCGTCGCTAGAAATTTCGACACTATTAGACTATCATTTCAATTGATGCGGCCTCCAAACAT

[0293] GACGCCAGCTGTTGCTGCACTGTTTCCAAATGCTCAACCTTTTGTTAATCACGCAACTGTCGGATTGACTCTCCGGAT

[0294] TGATTCAGCCATTTGTGAATCTGTGCTCGCTGATGCTACTGAAACAATGCTAGCCAACGTGACGGCTGTTAGACAAGA

[0295] ATACGCAGTTCCAGTTGGACCGGTATTTCCACCAGGTATGAATTGGACAGAGCTGATCACCAATTATTCTCCATCACG

[0296] CGAAGATAATTTACAGCGCGTATTTACTGTGGCTTCCATTAGAAGCATGCTTGTTAAGTGAGGACCAAGCTAACTACT

[0297] TGGTATCCGATCTTATCACGTATGTAGCTATATCAAGCTGCCCAGACTTTGCAAGTAAGG

[0298] VP7 gene (SEQ ID No.11):

[0299] CGTTGGGCTAGCGGTTAGCTCCTTTTAATGTATGGTATTGAATATACCACAGTTCTAACCTTTCTGATATCATTCATT

[0300] TTATTGAACTATATATTAAAATCTTTAACCAGAATGATGGACTTCATTATTTATAGATTTCTTTTCATCATAGTTATT

[0301] TTGCCACCATTACTGAAAGCTCAAAATTACGGGATCAATCTGCCAATTACTGGTTCAATGGATACTGCATACGCTAAT

[0302] TCTACACAGGAAGAAACTTTCCTCACATCAACTCTGTGTTTATATTATCCAACTGAAGCAGCGACAGAAATAAATGAT

[0303] AATTCATGGAAAGATACACTCTCTCAACTGTTTTTAACTAAGGGATGGCCCACCGGATCTGTTTATTTTAAAGAATATACT

[0304] GATATTGCTTCCTTTCAGTCGATCCAATTGTATTGTGATTATAACGTAGTGCTAATGAAATACGACGCAACTCTACAG

[0305] TTGGATATGTCCGAATTGGCTGATCTGATATTGAATGAATGGCTGTGCAACCCAATGGACATCACTTTATATTACTATCAA

[0306] CAAACGGATGAAGCTAATAAATGGATCTCTACGGGATCTTCGTGTACAATAAAAGTATGTCCACTTAATACACAGACT

[0307] CTTGGAATTGGTTGTTTAACTACTGATGCAACAACATTTGAAGAAGTTGCCACAGCCGAAAAATTAGTGATTACTGAC

[0308] GTTGTCGATGGAGTGAATCACAAACTTGATGTTACAACTACTACTTGTACTATTAGGAATTGTAAAAAATTGGGACCA

[0309] AGAGAAAACGTAGCGGTAATACAAGTTGGAGGTTCTGATGTTCTCGATATAACAGCTGACCCAACTACGGCACCACAA

[0310] ACTGAAAGAATGATGCGTATAAATTGGAAGAAATGGTGGCAAGTATTTTACACGGTAGTTGACTACGTAAATCAAATA

[0311] ATTCAAGCAATGTCCAAAAGATCACGGTCATTAAATTCTGCTGCATTCTACTATAGAGTTTAGGTATAGCTTTAG

[0312] By translating the above gene sequences, the amino acid sequences of 11 proteins of rotavirus are obtained.

[0313] NSP1 protein (SEQ ID No.12):

[0314] MATFKDACFHYRRITKLNRELLRIGANSVWTPVSSNKIRGWCIECCQLTELTFCHGCSLAHVCQWCIQNKRCFLDNEP

[0315] HLLKLRTFESPITKEKLQCIIDLYNLLFPISPGIINKFKKAVKQRKCRNELDKSWYNQLLLPITLNAAVFKFHSREVY

[0316] VFGFYEGSLSCTDLPYRLVNCIDLYDRLLLDQINFERMSSLPDNLQSIYANKYFKLSRLPSMKLKQIYYSDFSKQNLI

[0317] NKYKTKSRIVLRNLTEFTWASQTDLHHDLLNNKDKILAALSTSSLKQFETHDLNLGRVKADIFELGHHCKPNYISSNH

[0318] WQPASKISQCKWCNVKYAFRDMDWKMESMYNELLSFIQSCYKSNVNVGHCSSVESAYPLVKDILWHSITKYIDQAIEK

[0319] LFNVMNPTQVNDQQVISFHWQIDIALYMHIKMILKTEALPFTFTLDQFNSIIKGIVNQXCDVTELDLLPLCTEQTDKL

[0320] VKLEEEGKLSEEYELLISDSEDDD

[0321] NSP2 protein (SEQ ID No.13):

[0322] MAELACFCYPHLENDSYKFIPFNSLAIKCMLTAKVDKKDLDKFYNSIIYGIAPPPQFKKRYNTNDNSRGMNFETQMFT

[0323] KVAMLICEALNSLKITQTDVANVLSRVVSVRHLENLVLRKENHQDVLFHSKDLLIKSVLIAIGQSKEIETTATAEGGEIVF

[0324] QNAAFTMWKLTYLDHQLTPILDQNFVEYKVTLNEDKPISDGHVKELVAELRWQYNKFAVITHGKGHYRVVKYSSVANHADRVYATFKNNNKSGISSDFNLLDQRIIWQNWYAFTSSMKQGNTLDVCKKLLFQKMKQEKNPFRGLSTDRKMDEVSQVGV*FA NSP3 protein (SEQ ID No.14):

[0325] MLKMESQQQMASSIINSSFEAAVVAATSTLELMGIQYDYNEVYTRVKSKFDFVMDDSGVKNNLMGKAITIDQALNGKF

[0326] GSAIRNKNWMTDSRTVAKLDEDVNKLRMMLSSKGIDQKMRVLNACFSVKRVPGKSSSIIKCTRLMKDKLERGEVEVDD

[0327] SFVEEKMEIDTIDWKSRYEQLEKRFEALKHRVNEKYNNWVIKARKVNENMNSLQNVISQQQAHINELQMYNNKLERDL

[0328] QSKIGSVVSSIEWYLRSMELSDDVKSDIEQQLNSIDQLNPVNAMDDFESILRNLISDYDRLFLMFKGLLQQCNYTCTYE*LNELINDITIYT*PSMSTIVK

[0329] NSP4 protein (SEQ ID No.15):

[0330] VPRERVRKDGQAYRPQLHIECNHSNE*DVTYYNGGSWNGVFSIYCFCSNCVVYTA*SFDSYHENCP*NIKMFI*SS*ILYC INI*YSTEISWVQGTNYY*R*N*ETNGQSCKRDETSTGND**TNY*RNRTG*VT*TNS*HANN*TS**S*YVARIQSETF*NAK*MG*RRKSIRTKRSDCIFVRG*ATVVCLRKRRSS*Q*APSDLMIG*EATTSHIACDLVLIPFNQSSQCWTLMEGTV NSP5 protein (SEQ ID No.16):

[0331] Q*CLSVLT*QVFLLFLLVFINMNHLQQRQLFLENLLVGVNSTFHRMQKHSINTCCRSLQRILDHLILLRTIHSPVFRL DRMQLRQMQMLACLWIHRRNHDLQATLDVIKWISP*VKVLKSTLI*ILPFQCQQFLKRRSPNQTIKVGNTTQGLKQIP IQMNTYWMILIVMMGSVRTVNIRKSTLHSE*E*NKSQCN*LKICKSDLRTH*GAPHSV

[0332] VP1 protein (SEQ ID No.17):

[0333] MGKYNLILSEYLSFIYNSQSAVQIPIYYSSNSDLEKRCIEFHSKCLENSKKGLSLKNVFVEYKDVIENATLLSILSYS

[0334] YDKYNAVERKLVHYAKGKPLEADLNANELDYENNKLTSDLFPTAEEYTDSLMDPAILTSLSSNLNAVMFWLEKHANDT

[0335] AEKAKIYKRRLDLFTIVASTVNKYGVPRHNAKYRYEYDVMKDKPYYLVTWANSSIEMLMSVFSHEDYLIAKELIVLSY

[0336] SNRSTLAKLVSSPMSILVALVDINGTFITNEELELEFSNKYVKAIVPDQTFDELKEMLDNMKKAGLVDIPKMIQDWLV

[0337] DCSIEKFPLMAKIYSWSFHVGFRKQKMLDAALDQLKTEYTEDVDDEMYREYTMLIRDEVVNMLEEAVKHDDHLLQDSE

[0338] LAGLLSMSSASNGESRQLKFGRKTIFSTKKNMHVMDDMANGRYTPGVIPPVNVDKPIPLGRRDVPGRRTRIIFILPYE

[0339] YFIAQHAVVEKMLIYAKHTREYAEFYSQSNQLLSYGDVTRFLSNNAMVLYTDVSQWDSSQHNTQPFRKGIIMGLDMLA

[0340] NMTNDVKVIQTLHLYKQTQINLMDSYVQIPDGNVIKKIQYGAVASGEKQTKANSIANLALIKTVLSRIANKYSFVTK

[0341] IIRVDGDDNYAVLQFNTEVTKQMVQDVSNDVRDTYARMNAKVKALVSTVGIEIAKRYIAGGKIFFRAGINLLNNEKRG

[0342] QSTQWDQAAVLYSNYIVNRLRGFETDREFILTKIMQMTSVAITGSLRLFPSERVLTTNSTFKVFDSEDFIIEYGTTDD

[0343] EVYIQRAFMSLSSQKSGIADEIAASQTFKNYVSKLSDQLLVSKNAIVSRGIALTEKAKLNSYAPISLEKRRAQISALL

[0344] TMLQKPVTFKSNKITINDILHDIKPYFVMSEANLPMQYQKFMPTLPTNVQYIIQCIGSRTYQIEDDGSKSAISKLISK

[0345] YSVYRPSIEELYKVISLHEQEIQLYLVSLGVPKIDADTYIGSKIYSQDKYRILESYVYNLLSINYGCYQLFDFNSPDLEKLIRIPFKGKIPAVTFILHLYAKLEIINYAIKNGSWISLFCNYPKSEMIKLWKKMWNITSLRSPYTNFFQSYVQSEIDS*200 No.18):

[0346] GEKKGMPYRKRGARRETILKDDRMQEKEENKNVNGNVENKNVTCTQLSEKVLSQKEEVITDNQEEIKIADEVRKSSK

[0347] EESKQLLEVLCTKEEHQKEVQYEILQKTIPTFEPKESILKKLEDIKKKKKLFRIFEPKQLPIYRANKKELRN

[0348] RWYWKLKRDTLPDGDYDVREYFLNLYDQVLTEMPDYLLLKDMAVENKNSRDAGKVVDSETAAICDAIFQDEETEGVVR

[0349] RFIAEMRQRVQADRNVVNYPSILHPIDHAFNEYFLQHQLVEPLNNDIIFNYIPERIRNDVNYILNMDRNLPSTARYIR

[0350] PNLLQDRLNLHDNFESLWDTITTSNYILARSVVPDLKELVSTEAQIQKMSQDLQLEALTIQSETQFLTGINSQAANDC

[0351] FKTLIAAMLSQRTMSLDFVTTNYMSLISGMWLLTVIPNDMFIRESLVACQLAIINTIVYPAFGMQRMHYRNGDPQTPF

[0352] QIAEQQIQNFQVANWLHFVNNNQFRQVVIDGVLNQVLNDNIRNGHVVNQLMEALMQLSRQQFPTMPVDYKRSIQRGIL

[0353] LLSNRLGQLVDLTRLLAYNYETLMACITMNMQHVQTLTTEKLQLTSVTSLCMLIGNATVIPSPQTLFHYYNVNVNFHS

[0354] NYNERINDAVAIITAANRLNLYQKKMKSIVEDFLKRLQIFDVSRVPDDQMYRLRDRLRLLPVEIRRLDIFNLILMNME

[0355] QIERASDKIAQGVIIAYRDMQLERDEMYGYVNIARNLDGFQQINLEELMRTGDYAQITNMLLNNQPVALVGALPFITD

[0356] SSVISLIAKLDATVFAQIVKLRKVDTLKPILYKINSDSNDFYLVANYDWVPTSTTKVYKQVPQQFDFRASMHMLTSNLTFTVYSDLLAFVSADTVEPINAVAFDNMRIMSEL*

[0357] VP3 protein (SEQ ID No.19):

[0358] MKVLALRHSVAQVYADTQVYTHDDTKDSYENAFLISNLTTHNILYNYSTKTLEILNKSGIAAVEIQSLEELFTLIRC

[0359] NFTYDYENNIIYLHDYSYYTNNEIRTDQHWVTKTDIEEYLLPGWKLTYVGYNGNDTRGHYNFSFTCQNAATDDDLIIE

[0360] YIYSEALDFQNFMLKKIKERMTTSLPIARLSNRVFRDKLFPLLSKKHQRIVNVGPRNESMFTFFLNFPSIKQFSNGPYL

[0361] VKDTIKLKQERWLGKRISQFDIGQYKNMMNVITTVYHYYNLYQKKPTIYMVGSAPSYWIYDVKQYSDFMFETWDPLDT

[0362] PYSSVHHRELFFEKDIVKLKDDSILYIDIRTDRGNMNWKEWRKIVETQTINNLKLVYQYLASGKSKVCCVKMTAMDLE

[0363] LPISAKLLHHPTTEIRSEFYLLLDIWDVSNTKRFIPKGVLYSFINNVVTGNVFIQPPFKITKSKNDYIVALYALSNDF

[0364] NDRTDVVNLINNQKQSLITVRINNTFKDEPKVGFKNIYDWTFLPTDFSTTNAIVTSYDGCLGMFGLSISLASKPTGNN

[0365] HLFILSGTDKYYKLDQFANHTGISRRSHQVRFSESATSYSGYIFRDLSNNNFNLIGTNVENSVSGHVYNALIYYRYNY

[0366] SFDLKRWIYLHSIEKADIEGGRYYEHAPIELIYACRSAKEFASLQDDLTVLRYANEIERYINKVYSITYADDPNYFIG

[0367] VP4 protein (SEQ ID No.20): IKFKHIPYKYDVKIPHLTFGVLFISDNMIPDVVRIMKDMKKELFEMDVTTSYTYMLSDGIYVANVSGVLAAYFKMYNLFYKSQITFGQSRMFIPHITLSFSNNKTVRIETTELKISSIYLRKIRGDTVFDMSE*ARNLTH

[0368] MASLIYRQLLTNSYTVDLSDEIESIGSEKNQNVTINPGPFAQTGYAPVNWGPGEVNDSTTVEPTLDGPYQPTSFNPPV

[0369] NYWMLLAPLNAGVVVEGTNNTNRWLATILVEPGVASTTRTYTLFGIQEQITVENGSNTKWKFIDLMKTTSSGTYTQHS

[0370] PLLSEPKLYGIMKHGGQLWTYDGETPNAITNGYSTTNYDSVNMTSFCDFYIIPRSQESVCTEYINNGLPPMQNTRNIV

[0371] PVSISSRNIIHQRAQANEDIVVSKTSLWKEMKYNRDITIRFKFANAIIKSGGLGYKWSEISFKPANYQYTYIRDGEEV

[0372] TAHTTCSVNGVNDFSFNGGSLPTDFVISRYEVIKENSYVYXDYWDDSQAFRNMVYVRSLAADLNDVLCTGGDYSFALP

[0373] VGQWPVMTGGAVSLHSAGVTLSTQFTDFVSLNSLRFRFRLTVEEPYFSITRTRVTRLYGLPAANPNNNKEYYEVAGRF

[0374] SLISLVLSNDDYQTPIANSVTVRQDLERQLGELREEFNALSQEIAMSQLIDLALLPLDMFSMFSGIKSTIDAAKSMAT

[0375] NVMKKFKKSGLATSVSTLTDSLSDAASSISRGSSLRSVGSSASAWTDVSTQLTDVSSTVNTISTQTSTISRRLRLKEI

[0376] ATQTEGMNFDDISAAVLKTKIDKSTQIAPATLPDIVTEASEKFIPNRAYRVINNNEVLEAGTDGRFFAYRVETFEEIPFDVQKFADLVTDSPVISAIIDFKTLKNLNDNYGISREQAFNLLRSDPRVLREFINQDNPIIRNRIEQLILQCRL*

[0377] VP6 protein (SEQ ID No.21):

[0378] *RQNCRRHIILKCQ*PNTTI*PNDNYNEWQ*ISNGWNW*FTS*KLEF*FWLAWHNIA*S*RQLCRNCSNHN*IFR*LC RQRLYG*DG*RIAAEWNSSSVRCFKKIVRNKI*KN*L**FIRIYRELESTEQKTKNWIYFS*TKHFSVLSIIYPE*VS TAT**FNGYYVAKCRIRNSSCGI*LLLCYQRSSQYSTV*TYCTIAPCSDNSNYHTPSRCRKIQLSKSS*FR*WRYNVV FQSRSTAT**C*S*ISIEWPNN*YVSS*IWYNRR*KFRHY*TIISIDAASKHDASCCCTVSKCSTFC*SRNCRIDSPD*FSHL*ICAR*CY*NNASQRDGC*TRIRSSSWTGISTRYELDRADHQLFSITRR*FTARIYCGFH*KHAC*VRTKLTT WYPILSRM*LYQAAQTLQVR

[0379] VP7 protein (SEQ ID No.22):

[0380] RWASG*LLLMYGIEYTTVLTFLISFILLNYILKSLTRMMDFIIYRFLFIIVILPPLLKAQNYGINLPITGSMDTAYAN STQEETFLTSTLCLYYPTEAATEINDNSWKDTLSQLFLTKGWPTGSVYFKEYTDIASFSVDPQLYCDYNVVLMKYDATLQLDMSELADLILNEWLCNPMDITLYYYQQTDEANKWISTGSSCTIKVCPLNT QTLGIGCLTTDATTFEEVATAEKLVITDVVDGVNHKLDVTTTTCTIRNCKKLGPRENVAVIQVGGSDVLDITADPTTAPQTERMMRINWKKWWQVFYTVVDYVNQIIQAMSKRSRSLNSAAFYYRV*V*L*

[0381] Example 2 Determination of virus titer of human rotavirus strain XYR-19

[0382] Press 10 5.0 MA104 cells were added to a 6-well culture plate and cultured at 37°C for 3-4 days to form a dense monolayer. The XYR-19 strain was diluted 10-fold in series, and 6 dilutions were recorded as 10 -1 , 10 -2 , 10 -3 , 10 -4 , 10 -5 , 10 -6 Then inoculate in 6-well plate MA104 monolayer cells, inoculate two wells for each dilution, 500μl / well, and perform virus PFU titration. After 1 hour of adsorption culture at 37℃, add MEM cell maintenance medium without calf serum, add 1.0% agarose gel (LONZA, 50011), invert and culture at 37℃ for 3 days, add 1.0% agarose gel containing 0.02mg / ml final concentration of neutral red (Sigma, N2889-100ml), continue invert and culture at 37℃ for 4 days, and observe the results. The calculation method of virus plaque forming unit (PFU): the number of plaque forming units in 1ml virus = the number of plaques appearing in one well × virus dilution / the amount of virus inoculated in one well.

[0383] The virus titers of the harvest fluids of different generations of XYR-19 strain cultured on Vero cells are shown in Figure 5 It can be seen that the XYR-19 strain has good stability in passage. The titers of the XYR-19 strain cultured on Vero cells at different MOIs are shown in Figure 6It can be seen that the appropriate MOI range for the cultivation of XRY-19 strain is 0.05-0.3. The growth curve of XYR-19 strain on Vero cells is shown in Figure 7 , it can be seen that the appropriate harvest time for XRY-19 strain culture is 48h-120h.

[0384] Example 3 Evaluation of the immune efficacy of human rotavirus strain XYR-19

[0385] (1) Analysis of the immunogenicity of the XYR-19 rotavirus strain

[0386] The 7th generation virus harvested from Vero cells with a titer of 6.90LogPFU / ml was concentrated and purified, and then added with Freund's adjuvant and intramuscularly injected into 10 mice (BALB / c strain, weighing about 16g, and about 3 months old) twice (0 month and 1 month). Blood was collected at 0 and 28 weeks after immunization to separate serum for serum IgG antibody titer analysis and neutralizing antibody titer analysis.

[0387] (2) Evaluation experiment of specific rotavirus antibody IgG titer in immune serum

[0388] Sheep anti-rotavirus immune polyclonal antibody (Millipore, ab1129) was diluted 1:1000 with carbonate buffer (pH9.6), and 100 μl per well was coated on a 96-well ELISA plate at 4°C overnight; then the coating solution was removed, and the plate was washed three times with PBS solution containing 0.5% Tween-20 (PBST solution), each time for 3 minutes; PBST solution containing 3% bovine serum albumin (Solebol, A8020), 100 μl / well, was blocked at 37°C for 2 hours; the blocking solution was removed, the plate was washed with PBST, and purified rotavirus antigen (prepared and provided by the Molecular Biology Laboratory of the Institute of Medical Biology, Chinese Academy of Medical Sciences) was added to each well at 500 CCID50 / 100 μl ELISA plate, incubate at 37℃ for 1h; after washing, dilute the mouse immune serum to be tested by 2 times, add 100μl / well to the ELISA plate, bind at 37℃ for 1h; wash the plate with PBST, add HRP-labeled goat anti-mouse antibody (Proteintech, SA00001-1) diluted 1:5000 with PBST buffer, 100μl / well, bind at 37℃ for 1h; wash the plate with PBST, add 100μl / well of TMB colorimetric solution (Solebo, PR1200), color develop at room temperature for 5min, and then stop color development with stop solution (Biyuntian, P0215-500ml); detect the optical density value at 450nm with an enzyme reader (Biotech, Epoch2nsc). When the optical density value of the serum to be tested is 2.1 times that of the negative serum, the serum to be tested is considered positive, and the titer of serum antibodies is expressed as the reciprocal of the serum dilution. The detection system used purified inactivated rotavirus-immunized guinea pig serum as a positive reference, rotavirus-free PBS-immunized guinea pig serum as a negative reference, and HRP-labeled goat anti-guinea pig antibody diluted 1:5000 in PBST buffer as an enzyme-labeled secondary antibody to calibrate the effectiveness of the detection system.

[0389] After two immunizations, the XYR-19 strain can produce IgG antibodies with a titer higher than 8192 in mice (see Figure 8 ).

[0390] (3) Evaluation experiment of rotavirus neutralizing antibody titer in immune serum

[0391] Press 10 4 Cells / 100μl / well Add the digested and suspended MA104 cells to a 96-well cell culture plate and culture at 37°C for 3-4 days for the cells to grow into a dense monolayer. Dilute the isolated virus antiserum by 2-fold gradient, and add 60μl / well to a 96-well deep-well plate. Add 60μl of gradient dilution to 100CCID 50 The harvested viruses were neutralized in a 37°C CO2 incubator for 1 hour, and then inoculated into MA104 monolayer cells in a 96-well plate at 100 μl / well of the neutralizing solution. The cells were cultured at 37°C for 7 days and the results were observed.

[0392] After two immunizations with the XYR-19 strain, mice can produce anti-rotavirus neutralizing antibodies with a titer of more than 128 (see Fig. 9 ).

[0393] The above embodiments are only used to illustrate the present invention, but not to limit the present invention. Those skilled in the art may make various changes and modifications without departing from the essence and scope of the present invention. Therefore, all equivalent technical solutions also belong to the protection scope of the present invention.

Claims

1. A rotavirus A, whose deposit number is CGMCC No.26214.

2. A microbial preparation comprising rotavirus group A with the deposit number CGMCC No. 26214.

3. A method for culturing rotavirus group A, the method comprising: Vero cells were used as cell matrix and rotavirus A (CGMCC No. 26214) was inoculated for culture.

4. The method according to claim 3, comprising: Vero cells were used as the cell matrix. When the Vero cells grew to a monolayer, the virus inoculation amount was 0.05-0.3 MOI, and then MEM cell maintenance medium without calf serum was added. The culture was cultured at 37° C. for 48-120 hours, and the culture was harvested.

5. Nucleic acid of rotavirus A group CGMCC No. 26214, which includes one or more of the full gene, VP4 gene, VP7 gene, VP6 gene, and NSP3 gene of rotavirus A group CGMCC No. 26214; Furthermore, the nucleic acid may also include one or more of VP1 gene, VP2 gene, VP3 gene, NSP1 gene, NSP2 gene, NSP4 gene, and NSP5 gene.

6. Rotavirus A group CGMCC No. 26214 protein, including one or more of the whole protein, VP4 protein, VP7 protein, VP6 protein, and NSP3 protein of rotavirus A group CGMCC No. 26214; Furthermore, the protein may also include one or more of VP1 protein, VP2 protein, VP3 protein, NSP1 protein, NSP2 protein, NSP4 protein, and NSP5 protein of rotavirus group A CGMCC No.26214.

7. Use of the rotavirus group A according to claim 1, the nucleic acid according to claim 5, or the protein according to claim 6 in one or more of the following aspects: Preparation of rotavirus vaccines; Preparation of anti-rotavirus antibodies; Preparation of detection reagents for identifying rotavirus group A CGMCC No.26214.

8. A rotavirus vaccine, comprising the non-replicating rotavirus group A CGMCC No. 26214 of claim 1, the nucleic acid of claim 5, the protein of claim 6 and / or a specific immunogenic fragment derived from the rotavirus group A CGMCC No. 26214.

9. An anti-rotavirus antibody, which is a monoclonal antibody or a polyclonal antibody obtained by immunizing an animal with the rotavirus group A described in claim 1 or the protein described in claim 6.

10. A detection agent or kit for identifying rotavirus group A CGMCC No. 26214, comprising one or more of the following substances: Rotavirus group A CGMCC No. 26214 of claim 1; The nucleic acid according to claim 5; Specific amplification primers and / or probes for the nucleic acid according to claim 5; The protein according to claim 6; A specific binding antibody against the protein of claim 6.